Blueprint Medicines Corp. Cash flow Statement
Figures in Million
Consolidated Cash Flow Results
Dec'24
Dec'23
Dec'22
Dec'21
Dec'20
Dec'19
No of Months
12
12
12
12
12
12
Profit Before Tax
-65.00
-506.00
-552.00
-641.00
314.00
-347.00
Adjustment
0.00
0.00
0.00
0.00
0.00
0.00
Changes In working Capital
-64.00
-41.00
-53.00
-23.00
-15.00
9.00
Cash Flow after changes in Working Capital
0.00
0.00
0.00
0.00
0.00
0.00
Cash Flow from Operating Activities
-192.00
-436.00
-502.00
-298.00
387.00
-278.00
Cash Flow from Investing Activities
-47.00
274.00
-149.00
-225.00
-434.00
-16.00
Cash Flow from Financing Activities
273.00
119.00
561.00
50.00
617.00
340.00
Net Cash Inflow / Outflow
32.00
-43.00
-90.00
-474.00
570.00
46.00
Opening Cash & Cash Equivalents
0.00
0.00
0.00
0.00
0.00
0.00
Cash & Cash Equivalent on Amalgamation / Take over / Merger
0.00
0.00
0.00
0.00
0.00
0.00
Cash & Cash Equivalent of Subsidiaries under liquidations
0.00
0.00
0.00
0.00
0.00
0.00
Translation adjustment on reserves / op cash balances foreign subsidiaries
0.00
0.00
0.00
0.00
0.00
0.00
Effect of Foreign Exchange Fluctuations
0.00
0.00
0.00
0.00
0.00
0.00
Closing Cash & Cash Equivalent
0.00
0.00
0.00
0.00
0.00
0.00
Figures in USD Million
Seasonal companies are compared with the same quarter last year
Seasonal companies are compared with the same quarter last year
Compare Cash Flow Results of Blueprint Medicines Corp.
Figures in Million
consolidated Cash Flow Results
Change(USD)
Change(%)
Profit Before Tax
-65.863
95.356
-160.00
-169.07%
Adjustment
0
0
0.00
0.00%
Changes In working Capital
-64.685
-14.457
-50.00
-347.43%
Cash Flow after changes in Working Capital
0
0
0.00
0.00%
Cash Flow from Operating Activities
-192.586
123.42
-315.00
-256.04%
Cash Flow from Investing Activities
-47.501
-163.439
116.00
70.94%
Cash Flow from Financing Activities
273.111
27.014
246.00
911.00%
Net Cash Inflow / Outflow
32.115
-13.463
45.00
338.54%
Opening Cash & Cash Equivalents
0
0
0.00
0.00%
Cash & Cash Equivalent on Amalgamation / Take over / Merger
0
0
0.00
0.00%
Cash & Cash Equivalent of Subsidiaries under liquidations
0
0
0.00
0.00%
Translation adjustment on reserves / op cash balances foreign subsidiaries
0
0
0.00
0.00%
Effect of Foreign Exchange Fluctuations
-0.909
-0.458
0.00
-98.47%
Closing Cash & Cash Equivalent
0
0
0.00
0.00%
Cash Flow - Snapshot (Consolidated) - Dec'24
YoY Growth in year ended Dec 2024 is 55.91% vs 13.03% in Dec 2023
Dec'24
Dec'23
Change(%)
Cash Flow from Operating Activities
-192.59
-436.85
55.91%






